ReviewAdvances in experimental medicine and biology2026
Roles of Core Fucosylation in Neuroinflammation and Its Possibility for Application.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Core fucosylation, a critical post-translational modification mediated by α1,6-fucosyltransferase (Fut8), is vital in regulating cellular functions and signaling pathways. This glycosylation process is particularly significant in the context of the central nervous system (CNS), where it influences neurodevelopment, synaptic functionality, and the neuroinflammatory response. Aberrations in core fucosylation have been implicated in the pathogenesis of various neuroinflammatory conditions, underscoring its potential as a therapeutic target for neurological disorders. Core fucosylation affects several important signaling molecules and receptors, such as the transforming growth factor-β (TGF-β) receptor, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), integrins, and glycoprotein 130 (gp130). These molecules are essential for maintaining CNS homeostasis and responding to injury or disease. Furthermore, the dysregulation of core fucosylation has been associated with altered microglial and astrocytic responses to inflammatory stimuli, affecting the progression of neurodegenerative diseases. The modulation of core fucosylation pathways presents a promising avenue for developing novel therapeutic strategies to control neuroinflammation and improve outcomes in patients with neurodegenerative disorders. In conclusion, the intricate relationship between core fucosylation and neuroinflammation offers insights into the molecular mechanisms underlying CNS pathologies and highlights the importance of further research in this area to identify new targets for therapeutic intervention.
Indexed as
Identifiers
41917387What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.